NASDAQ:SCYX SCYNEXIS - SCYX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.74 +0.03 (+1.75%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.71▼$1.7950-Day Range$1.44▼$2.4552-Week Range$1.42▼$5.27Volume88,908 shsAverage Volume86,937 shsMarket Capitalization$56.83 millionP/E RatioN/ADividend YieldN/APrice Target$7.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media SCYNEXIS MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside340.6% Upside$7.67 Price TargetShort InterestHealthy2.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector436th out of 1,030 stocksPharmaceutical Preparations Industry216th out of 502 stocks 3.5 Analyst's Opinion Consensus RatingSCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.67, SCYNEXIS has a forecasted upside of 340.6% from its current price of $1.74.Amount of Analyst CoverageSCYNEXIS has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.69% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in SCYNEXIS has recently decreased by 5.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SCYX. Previous Next 1.3 News and Social Media Coverage News SentimentSCYNEXIS has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.Search InterestOnly 5 people have searched for SCYX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.36% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions49.92% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SCYNEXIS are expected to grow in the coming year, from ($1.87) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SCYNEXIS (NASDAQ:SCYX) StockSCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.Read More Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address SCYX Stock News HeadlinesJanuary 14, 2023 | finance.yahoo.comSCYNEXIS (NASDAQ:SCYX) shareholders are up 14% this past week, but still in the red over the last five yearsDecember 17, 2022 | finance.yahoo.comSCYNEXIS, Inc. (SCYX) Stock Historical Prices & Data - Yahoo FinanceFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 13, 2022 | msn.comSCYNEXIS's Return On Capital Employed OverviewDecember 1, 2022 | finance.yahoo.comSCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal CandidiasisNovember 11, 2022 | finance.yahoo.comSCYNEXIS Third Quarter 2022 Earnings: Misses ExpectationsNovember 7, 2022 | finance.yahoo.comSCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of FungiNovember 2, 2022 | finance.yahoo.comEarnings Preview: Scynexis (SCYX) Q3 Earnings Expected to DeclineFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 1, 2022 | finance.yahoo.comSCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9October 30, 2022 | seekingalpha.comScynexis: No Compelling Reason To InvestOctober 25, 2022 | finance.yahoo.comBiopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial OfficerOctober 24, 2022 | finance.yahoo.comSCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022October 20, 2022 | globenewswire.comSCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal - GlobeNewswireOctober 11, 2022 | streetinsider.comScynexis (SCYX) to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp - StreetInsider.comOctober 11, 2022 | globenewswire.comSCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022 - GlobeNewswireOctober 11, 2022 | finance.yahoo.comSCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022October 9, 2022 | finance.yahoo.comGreat news for SCYNEXIS, Inc. (NASDAQ:SCYX): Insiders acquired stock in large numbers last year - Yahoo FinanceOctober 7, 2022 | finance.yahoo.comGreat news for SCYNEXIS, Inc. (NASDAQ:SCYX): Insiders acquired stock in large numbers last yearSeptember 30, 2022 | reuters.comSCYX.O - SCYNEXIS Inc | Stock Price & Latest News | ReutersSeptember 9, 2022 | benzinga.comSCYNEXIS (NASDAQ:SCYX) – Looking Into SCYNEXIS's Return On Capital Employed - BenzingaSeptember 9, 2022 | globenewswire.comSCYNEXIS to Participate in Upcoming September Investor Conferences - GlobeNewswireSeptember 9, 2022 | finance.yahoo.comSCYNEXIS to Participate in Upcoming September Investor ConferencesSeptember 8, 2022 | finance.yahoo.comSCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting - Yahoo FinanceSeptember 8, 2022 | finance.yahoo.comSCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial MeetingSeptember 1, 2022 | globenewswire.comSCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022 - GlobeNewswireSeptember 1, 2022 | finance.yahoo.comSCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address SCYX Company Calendar Last Earnings11/09/2022Today2/02/2023Next Earnings (Estimated)4/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees38Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.67 High Stock Price Forecast$8.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+340.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,870,000.00 Net Margins-1,864.15% Pretax Margin-1,977.02% Return on Equity-275.25% Return on Assets-82.05% Debt Debt-to-Equity Ratio2.63 Current Ratio7.26 Quick Ratio7.21 Sales & Book Value Annual Sales$13.16 million Price / Sales4.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book1.01Miscellaneous Outstanding Shares32,660,000Free Float31,233,000Market Cap$56.83 million OptionableOptionable Beta2.01 Key ExecutivesDavid Angulo GonzalezPresident, Chief Executive Officer & DirectorIvor MacLeodChief Financial & Accounting OfficerNkechi AzieVP-Clinical Development & Medical AffairsJim MaffezzoliVice President-Marketing & SalesScott SukenickSecretary & General CounselKey CompetitorsInfinity PharmaceuticalsNASDAQ:INFIBolt BiotherapeuticsNASDAQ:BOLTHepion PharmaceuticalsNASDAQ:HEPAPyxis OncologyNASDAQ:PYXSNabriva TherapeuticsNASDAQ:NBRVView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 285,834 shares on 11/15/2022Ownership: 4.048%Citadel Advisors LLCSold 5,700 shares on 11/15/2022Ownership: 0.000%UBS Oconnor LLCBought 29,428 shares on 11/14/2022Ownership: 1.640%Worth Venture Partners LLCSold 69,908 shares on 11/14/2022Ownership: 1.502%Dimensional Fund Advisors LPBought 17,006 shares on 11/10/2022Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions SCYX Stock - Frequently Asked Questions Should I buy or sell SCYNEXIS stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCYX shares. View SCYX analyst ratings or view top-rated stocks. What is SCYNEXIS's stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month price objectives for SCYNEXIS's shares. Their SCYX share price forecasts range from $7.00 to $8.00. On average, they anticipate the company's stock price to reach $7.67 in the next year. This suggests a possible upside of 340.6% from the stock's current price. View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts. How have SCYX shares performed in 2023? SCYNEXIS's stock was trading at $1.56 at the start of the year. Since then, SCYX shares have increased by 11.5% and is now trading at $1.74. View the best growth stocks for 2023 here. When is SCYNEXIS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. View our SCYX earnings forecast. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) released its earnings results on Wednesday, November, 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.11. The firm earned $1.56 million during the quarter, compared to analyst estimates of $1.89 million. SCYNEXIS had a negative net margin of 1,864.15% and a negative trailing twelve-month return on equity of 275.25%. When did SCYNEXIS's stock split? SCYNEXIS shares reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS). What is SCYNEXIS's stock symbol? SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX." Who are SCYNEXIS's major shareholders? SCYNEXIS's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wealth Effects LLC (0.19%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick. View institutional ownership trends. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SCYNEXIS's stock price today? One share of SCYX stock can currently be purchased for approximately $1.74. How much money does SCYNEXIS make? SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $56.83 million and generates $13.16 million in revenue each year. The company earns $-32,870,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. How can I contact SCYNEXIS? SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490. This page (NASDAQ:SCYX) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.